Healthcare / Drug Manufacturers - Specialty & GenericStockholm
$0.69
+0.01 (+1.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-24.8M · quality 56.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$161M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-41.1%
↓Gross Margin
972.8%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-3616.0%
FCF / Net income
0.95x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $687000.0 · net income $-26.2M · FCF $-24.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $687000.00 | $687000.00 | $675000.00 | — | — |
| Net Income | $-26.2M | $-26.2M | $-17.4M | $-13.7M | $-14.8M |
| EBITDA | $-17.7M | $-17.7M | $-13.6M | $-13.0M | $-14.8M |
| EPS | — | — | -0.16 | -0.37 | -0.40 |
| Gross Margin | 972.8% | 972.8% | 1143.3% | — | — |
| Operating Margin | -3856.3% | -3856.3% | -2575.6% | — | — |
| Net Margin | -3812.2% | -3812.2% | -2577.5% | — | — |
| Balance Sheet | |||||
| Current Ratio | 4.31 | 4.31 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-24.8M | $-24.8M | $-27.2M | $-18.3M | $-18.7M |
| Returns | |||||
| ROE | -41.1% | -41.1% | -42.6% | -28.8% | -32.4% |
| Valuation | |||||
| P/B | 2.53 | 2.53 | 1.73 | 0.84 | 1.25 |
| Growth & Yield | |||||
| Revenue Growth | 1.8% | 1.8% | — | — | — |
| EPS Growth | — | — | 57.0% | 6.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-22.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.16 → n/d
Residual
-22.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.